GlassScriptPhysician profile
Daniel W Gembus
NPI 1255301941
$560.92
in general payments reported to CMS, 2019-2025
11 companies · $535 in 2025
The $535 reported for 2025 was more than what 91% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.28 · 2021: $13.53 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $535.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $535.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $145.19 | 2025 | Eligard, Jatenzo, Rubraca |
| Janssen Biotech, INC. | $84.87 | 2025 | Erleada |
| Immunitybio, INC. | $77.57 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.12 | 2025 | |
| Pharmaand Gmbh | $37.70 | 2025 | Rubraca |
| Blue Earth Diagnostics | $33.34 | 2025 | Posluma |
| Merck Sharp & Dohme LLC | $27.25 | 2021-2025 | Keytruda Qlex, Keytruda |
| Progenics Pharmaceuticals, INC. | $22.50 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.34 | 2025 | Lynparza |
| Zimmer Biomet Holdings, INC. | $12.28 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gembus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.